Table I.
Characteristics of HCT Recipientsa
| Number of participants | 77 |
| Demographic characteristics | |
| Gender (male/female) | 46/31 |
| Age (year) | 45 [18–73] |
| Adjusted ideal body weight (kg) | 70.9 [42.2–95.0] |
| Height (cm) | 172.0 [82.9–191] |
| Body surface area (m2) | 1.92 [1.30–2.59] |
| HCT characteristics | |
| Type of conditioning | |
| Nonmyeloablative | 17 |
| Myeloablative | 60 |
| Fludarabine administration (yes/no) | 16/61 |
| Donor type (HLA-matched related/unrelated) | 58/19 |
| Concomitant calcineurin inhibitor | |
| Tacrolimus | 24 |
| Cyclosporine | 53 |
| Biochemistryb | |
| Serum creatinine (mg/dL) | 0.8 [0.3–5.7] |
| Creatinine clearance (ml/min) | 92 [46.7–159] |
| Serum alanine aminotransferase (U/L) | 23 [8–717] |
| Serum aspartate aminotransferase (U/L) | 20 [7–204] |
| Serum alkaline phosphatase (U/L) | 68 [30–366] |
| Serum lactate dehydrogenase (U/L) | 190 [87–1697] |
| Serum total bilirubin (μmol/L) | 0.9 [0.2–37.5] |
| Serum direct bilirubin (μmol/L) | 0.2 [0.1–23.7] |
| Serum albumin (g/dL) | 3 [1.7–3.9] |
a
categorical data presented as number of participants meeting stated criteria; continuous data presented as median [min-max];
b
obtained within the seven days before MPA pharmacokinetic sampling